mohd izzuan
- BioMarin Pharmaceutical (BMRN) said that it would incur an acquired in-process research and development (IPR&D) expense of $283M for Q3.
- As a result, GAAP and non-GAAP diluted EPS for the quarter will be negatively impacted by $1.50.
- The non-GAAP diluted EPS estimate for the quarter is $1.25.